The Effect of Imatinib Treatment Duration on the Quality of the Life of Patients with Chronic Myeloid Leukemia
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F13%3A00071569" target="_blank" >RIV/00216224:14110/13:00071569 - isvavai.cz</a>
Výsledek na webu
<a href="http://dx.doi.org/10.4172/2155-9864.1000167" target="_blank" >http://dx.doi.org/10.4172/2155-9864.1000167</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.4172/2155-9864.1000167" target="_blank" >10.4172/2155-9864.1000167</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
The Effect of Imatinib Treatment Duration on the Quality of the Life of Patients with Chronic Myeloid Leukemia
Popis výsledku v původním jazyce
Purpose: The objective of this study was to evaluate the quality of life (QL) as well as the frequency and severity of depression in patients with chronic phase chronic myeloid leukemia (CP-CML) in relation to the duration of Imatinib treatment. Methods:A detailed analysis of 56 adult patients with CP CML divided into groups according to the length of Imatinib treatment was performed as follows: Group A (n=28)- patients treated for 15 months (median); and Group B (n=28)-patients treated for 50 months (median). All used questionnaires EORTC QLQ-C30 (version 2), SF 36 and BDI were localized and validated. Results: The results from the QL questionnaires found a trend in the improvement in the QL of patients treated with Imatinib for 50 months (median) compared to patients treated for 15 months (median) only. However, a statistically significant improvement in the QL of patients with longer Imatinib treatment was found only in patients without co-existing invalidity and/or rheumatic disea
Název v anglickém jazyce
The Effect of Imatinib Treatment Duration on the Quality of the Life of Patients with Chronic Myeloid Leukemia
Popis výsledku anglicky
Purpose: The objective of this study was to evaluate the quality of life (QL) as well as the frequency and severity of depression in patients with chronic phase chronic myeloid leukemia (CP-CML) in relation to the duration of Imatinib treatment. Methods:A detailed analysis of 56 adult patients with CP CML divided into groups according to the length of Imatinib treatment was performed as follows: Group A (n=28)- patients treated for 15 months (median); and Group B (n=28)-patients treated for 50 months (median). All used questionnaires EORTC QLQ-C30 (version 2), SF 36 and BDI were localized and validated. Results: The results from the QL questionnaires found a trend in the improvement in the QL of patients treated with Imatinib for 50 months (median) compared to patients treated for 15 months (median) only. However, a statistically significant improvement in the QL of patients with longer Imatinib treatment was found only in patients without co-existing invalidity and/or rheumatic disea
Klasifikace
Druh
J<sub>x</sub> - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
CEP obor
FD - Onkologie a hematologie
OECD FORD obor
—
Návaznosti výsledku
Projekt
—
Návaznosti
Z - Vyzkumny zamer (s odkazem do CEZ)
Ostatní
Rok uplatnění
2013
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Journal of Blood Disorders & Transfusion
ISSN
2155-9864
e-ISSN
—
Svazek periodika
4
Číslo periodika v rámci svazku
6
Stát vydavatele periodika
GB - Spojené království Velké Británie a Severního Irska
Počet stran výsledku
5
Strana od-do
1000167
Kód UT WoS článku
—
EID výsledku v databázi Scopus
—